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Abstract
Data on clinical use of ponatinib are limited. This prospective registry aimed to evaluate outcomes of ponatinib treatment in
routine practice over 3 years (2016–2019) in Belgium (NCT03678454). Patients with chronic myeloid leukemia (CML) or
Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) were treated with ponatinib per current
label. Fifty patients (33 CML and 17 Ph+ ALL) were enrolled. Fifty-five percent of CML and 29% of Ph+ ALL patients
had received ≥3 prior tyrosine kinase inhibitors (TKIs). Reasons for starting ponatinib were intolerance (40%), relapse or
refractoriness (28%) to previous TKIs, progression (16%), or T315I mutation (16%). Median follow-up was 15 months for
CML and 4.5 months for Ph+ ALL patients. Best response was a major molecular response in 58% of CML and 41% of Ph+
ALL patients. Of 20 patients who started ponatinib due to intolerance to previous TKIs, 9 (64%) CML and 4 (67%) Ph+
ALL achieved a major molecular response. Three-year estimates of overall survival were 85.3% and 85.6%, respectively, in
CML and Ph+ ALL patients; estimated progression-free survival was 81.6% and 48.9%. Adverse reactions were reported in
34 patients (68%); rash (26%) and dry skin (10%) were most common. Reported cardiovascular adverse reactions included
vascular stenosis (3), arterial hypertension (2), chest pain (1), palpitations (1), and vascular occlusion (1). This Belgian
registry confirms results from the PACE clinical trial and supports routine ponatinib use in CML and Ph+ ALL patients who
are resistant or intolerant to previous TKIs or with the T315I mutation.
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Introduction
Treatment with tyrosine kinase inhibitors (TKIs) has led to a
major improvement in the prognosis of patients with chronic
myeloid leukemia (CML) and Philadelphia chromosome-
positive (Ph+) acute lymphoblastic leukemia (ALL) [1].
TKIs selectively target the constitutively active BCR-ABL1
tyrosine kinase, therefore suppressing the growth of malignant
cells [2]. One of the challenges in TKI therapy is the develop-
ment of resistance, in many cases through the presence or
acquisition of mutations in the ABL kinase domain [2]. In
addition, some patients become intolerant to TKI treatment
by developing adverse events (AEs) that cannot always be
managed through dose reductions or symptomatic treatment
[3]. These AEs are a real challenge in the daily practice of
hematologists.
Currently, several TKIs are used in clinical practice, i.e.,
imatinib, nilotinib, dasatinib, bosutinib, and ponatinib [4].
Ponatinib is a third-generation TKI with potent activity against
native and mutated BCR-ABL1 containing single point muta-
tions, including the T315I mutation, for which no other
marketed TKI is effective [5, 6]. Ponatinib received marketing
approval based on the results of the phase 2 Ponatinib Ph+
ALL and CML Evaluation (PACE) trial, which demonstrated
the efficacy and safety of ponatinib in patients with CML or
Ph+ ALL who were intolerant or resistant to previous lines of
TKI therapy [7, 8]. By 12 months, 56% of chronic phase (CP)-
CML patients achieved a major cytogenetic response (MCyR;
primary endpoint) [7]. The 5-year follow-up data of this trial
showed deep and durable responses to ponatinib therapy in CP-
CML patients [8]. In total, 60% of the evaluable CP-CML
patients achieved MCyR, and the probability of maintaining
MCyR for 5 years was 82%. Fifty-four percent of evaluable
CP-CML patients achieved a complete cytogenetic response
(CCyR) and 40% achieved a major molecular response
(MMR, defined as BCR-ABL1 mRNA levels ≤0.1% on the
International Scale). Ponatinib dose reductions were proactive-
ly implemented during the course of the trial to decrease the
risk of arterial occlusive events (AOEs). The response to ther-
apy was maintained 40 months after ponatinib dose reduction
by ≥90% of patients who had achieved MCyR or MMR. Five-
year estimated rates of progression-free survival (PFS) and
overall survival (OS) were 53% and 73%, respectively [8]. In
Ph+ ALL patients, the efficacy data demonstrated promising
results, with 41% of patients having a major hematologic re-
sponse, 47% MCyR, and 38% CCyR [8].
The most common treatment-emergent AEs reported in the
PACE trial were rash, abdominal pain, thrombocytopenia,
headache, dry skin, and constipation. AOEs received special
attention in the clinical trial, as they can provoke dramatic con-
sequences for the patients. The cumulative incidence of AOEs
in all patients was 17.1% (11.8% serious AOE) in the initial
report and 25% (20% serious AOE) in the 5-year follow-up of
the PACE trial. The risk for AOE incidence appeared to be
related to ponatinib dose and pre-existing cardiovascular risk
factors [7, 8].
Despite ponatinib’s authorization in Europe since 2013 [9],
data on the use of ponatinib in routine clinical practice are
scarce. Nevertheless, collection of such data is important to
evaluate the effectiveness and safety of ponatinib and may help
optimize the use of ponatinib in daily practice. This registry is,
to our knowledge, the first report of prospective data of patients
with CML or Ph+ALL treated with ponatinib in routine clinical
practice.
Methods
Registry design and patients
This multi-center, prospective, observational study is currently
ongoing at 20 centers throughout Belgium (clinicaltrials.gov
identifier: NCT03678454). Patients ≥18 years old, diagnosed
with CML (all phases) or Ph+ ALL, and who started ponatinib
treatment according to the indication in the product label [9]
betweenMarch 1, 2016, the date of reimbursement in Belgium,
and March 1, 2019, were eligible for this enrolment period. In
addition, patients, who had participated in a named patient
program (NPP) for ponatinib prior to reimbursement but were
still being treated with ponatinib on March 1, 2016, were
also allowed to participate. Patients were excluded if they
participated in a clinical trial at any time during the registry
period (Fig. 1).
This registry was conducted in accordance with the
Declaration of Helsinki and the International Council for
Harmonization guidelines for good clinical practice. All patients
provided written informed consent before data collection, but a
waiver was granted by the ethics committee (EC) for NPP
patients who were still on ponatinib treatment on March 1,
2016, but deceased before the registry start. The registry protocol
and the informed consent form were approved by the central EC
and local ECs at each participating center; any subsequent
amendments were approved by the central EC and notified to
local ECs.
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All procedures related to registry conduct, including data
management, statistical analysis, and scientific writing, were
performed by Modis, Wavre, Belgium.
Data collection
All data used in the current analysiswere collected as of treatment
initiation. Data from registry start (which occurred approximately
10 months after reimbursement date) until month 36 were
collected prospectively. As treatment initiation could be earlier
than registry start, databetweenMarch1,2016 (dateof reimburse-
ment) and registry start were collected retrospectively. For the 8
patients treated in the NPP and still on treatment at registry start,
data that had been collected in the NPP were transferred to the
database for this registry.Safetydatawerenot collectedduring the
NPP. However, for NPP patients who participated in the registry,
safety data were also collected retrospectively between March 1,
2016 and registry start and prospectively as of registry start.
Data were collected during routine treatment visits in the
hospital or at least every 6 months. Documentation and date of
informed consent, participation in NPP, patient demographics,
disease characteristics, medical history, treatment patterns,
treatment outcomes, and safety were collected. All AEs had
to be reported based on a pre-defined AE list (Supplementary
Table S1), with the option to describe any AE not included in
the list, and were followed up until the outcome of the event
was established. For all AEs, a possible causal relationship
to ponatinib was assessed by the investigator. Responses to
treatment for each patient were measured as per routine
clinical practice and were defined according to the European
LeukemiaNet 2013 recommendations [10]. Mutation testing
was done as per routine clinical practice [10].
Data analysis
Data were analyzed using descriptive statistics. OS and PFS
curves were generated using the Kaplan–Meier method. The
sample size was not pre-defined. The primary analysis was
performed on the overall population. To identify any potential
selection bias due to inclusion of patients who had participated
to the NPP, a secondary analysis was performed excluding
these patients. Subgroup analyses were also performed by
disease (Ph+ ALL versus CML), and within the disease for
those who started ponatinib due to intolerance or another rea-
son than intolerance (i.e., progression, relapse, refractoriness,
or T315Imutation). Subgroup analyses were also performed for
patients who underwent an allogeneic stem cell transplantation
before starting ponatinib treatment and for patients with
MMR as best response to ponatinib. A sensitivity analysis
was performed to investigate a potential imbalance in the




A total of 33 patients with CML and 17 with Ph+ ALL were
included in this registry (Table 1). Among the CML patients,
30 were in chronic phase, 1 in accelerated phase, 1 in blastic
myeloid phase, and 1 in blastic lymphoid phase. Out of 11
CML and 10 Ph+ ALL patients with mutations in the BCR-
ABL1 kinase domain, 6 (55%) CML and 6 (60%) Ph+ ALL
patients had the T315Imutation. No mutations were detected
in 19 (58%) patients with CML and 7 (41%) patients with
Ph+ ALL, and mutation status was not determined for 3
(9%) patients with CML. Median age was 58 (19–83) years
for CML and 56 (28–80) years for Ph+ ALL patients
(Table 1). In total, 39% of CML and 35% of Ph+ ALL
patients had a history of cardiovascular disease, 33% of
CML and 35% of Ph+ ALL patients presented with arterial
hypertension, 15% of CML and 18% of Ph+ ALL patients
had diabetes mellitus, 12% of CML and 6% of Ph+ ALL
Fig. 1 Study design. D, day; M, month; CML, chronic myeloid leukemia; Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukemia;
D0, the start of reimbursement of ponatinib in Belgium, i.e., March 1, 2016
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patients had hyperlipidemia, and 30% of CML and 18% of
Ph+ ALL patients were smokers. One patient with Ph+
ALL had a history of heart failure.
Previous treatment
Among patients with CML, 3 (9%) received 1 previous
line of TKI treatment (all with T315I mutation), 12
(36%) received 2 previous lines, and 18 (55%) received
3 or more previous lines (Table 1). The corresponding
numbers among Ph+ ALL patients were 1 (6%), 11
(65%), and 5 (29%), respectively. None of the Ph+ ALL
patients had received more than 3 lines of different TKIs.
Imatinib was the most commonly used first-line TKI,
being used by 22 (67%) CML and 16 (94%) Ph+ ALL pa-
tients, while dasatinib was the most common second-line
TKI, used in 19 (58%) CML and 14 (82%) Ph+ ALL
patients. Nilotinib was used as a third-line therapy in 7
(21%) CML and 4 (24%) Ph+ ALL patients, and bosutinib
as a fourth-line therapy in 4 (12%) CML patients. Two
(6%) patients with CML and 6 (35%) patients with Ph+
ALL had received an allogeneic stem cell transplantation
prior to ponatinib treatment.
Ponatinib treatment
Treatment with ponatinib was started in 14 patients with CML
due to intolerance to previous TKI (42%), in 6 patients due to
progression on previous TKI (18%), in 9 patients due to re-
lapse or refractoriness (absence of response, primary refracto-
riness, hematological or cytogenetic relapse) to previous TKI
(27%), and in 4 patients due to the T315I mutation (12%).
Among Ph+ ALL patients, reasons to start treatment with
ponatinib were intolerance to previous TKI (6, 35%), disease
progression (2, 12%), relapse or refractoriness (absence of
response, primary refractoriness, hematological or cytogenetic
relapse [5, 30%]), or the T315I mutation (4, 24%) (Fig. 2).







Age in years, median (range) 58 (19–83) 58 (19–83) 56 (28–80)
Age in years, mean (SD) 56.2 (15.56) 56.8 (15.62) 55.1 (15.86)
Female, n (%) 19 (38%) 12 (36%) 7 (41%)
Previous TKI lines, n (%)
1 TKI 4 (8%) 3 (9%) 1 (6%)
2 TKIs 23 (46%) 12 (36%) 11 (65%)
≥3 TKIs 23 (46%) 18 (55%) 5 (29%)
Presence of mutations, n (%)
T315I 12 (24%) 6 (18%) 6 (35%)
Other 10 (20%) 5 (15%) 5 (29%)a
Not determined 3 (6%) 3 (9%) -
Medical history, n (%)
Liver disorder 2 (4%) - 2 (12%)
Pancreas disorder 2 (4%) 2 (6%) -
Reduced kidney function 6 (12%) 2 (6%) 4 (24%)
Hypertension 17 (34%) 11 (33%) 6 (35%)
Cardiovascular disease 19 (38%) 13 (39%) 6 (35%)
Smoking 13 (26%) 10 (30%) 3 (18%)
Diabetes 8 (16%) 5 (15%) 3 (18%)
Hyperlipidemia 5 (10%) 4 (12%) 1 (6%)
Hypercholesterolemia 6 (12%) 2 (6%) 4 (24%)
Significant alcohol abuse 4 (8%) 4 (12%) -
Other 36 (72%) 21 (64%) 15 (88%)
CML chronic myeloid leukemia; Ph+ALL Philadelphia chromosome-positive acute lymphoblastic leukemia; TKI
tyrosine kinase inhibitor; SD standard deviation; N total number of patients; n number of patients in respective
category
a In total, there were 10 Ph+ ALL patients with mutations. One patient had a T315Imutation and another mutation
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The time from CML or Ph+ ALL diagnosis and the start of
ponatinib treatment varied, ranging from 44 to 8139 days for
CML patients andfrom158to3632days for Ph+ ALL patients.
The majority of patients (70% of CML and 76% of Ph+ ALL)
received ponatinib at the starting dose of 45 mg/day. The
starting dose of 30 mg/day was used in 12% of patients with
CML and in 12% of patients with Ph+ ALL, and the starting
dose of 15 mg/day was used in 15% of patients with CML and
in 12% of patients with Ph+ ALL. One patient with CML
started the therapy with 15 mg of ponatinib every other day.
There was a difference over time in the proportion of CML
patients receiving the registered 45 mg/day starting dose of
ponatinib: Among the first 10 patients included in the registry,
86% of CML patients received a starting dose of 45 mg/day,
while in the last 10 included patients, only 43% of CML
patients started with 45 mg/day.
Treatment outcomes
The median follow-up was 449 days (range, 15–2777) and
135 days (range, 26–2114) for patients with CML and Ph+
ALL, respectively. The median duration of ponatinib treat-
ment was 380 days (range, 15–2777) for CML patients and
123 days (range, 13–2114) for Ph+ ALL patients. A swimmer
plot detailing treatment duration and outcomes and of all
individual patients in the registry is presented in Fig. 3.
MMR (BCR-ABL1 mRNA ≤0.1%) was achieved as best
response by 26 patients: 19 (58%) patients with CML and 7
(41%) patients with Ph+ ALL (Fig. 4). Of the CML patients
who started with ponatinib at 45 mg/day, 30 mg/day, and 15
mg/day, respectively, 15 out of 23 (65%), none out of 4 and 3
out of 5 (60%) achieved MMR as best response. Also, the
only CML patient starting at 15 mg every other day achieved
MMR. Of the Ph+ ALL patients who started with 45 mg/day,
30 mg/day, and 15 mg/day, respectively, 6 out of 13 (46%),
none out of 2 and 1 out of 2 (50%) achieved MMR as best
response. Two (6%) patients with CML and 3 (18%) patients
with Ph+ ALL achieved CCyR as best response (including 1
patient with Ph+ ALL who had CCyR before starting
ponatinib treatment) and 1 patient from each group (3% and
6% of CML and Ph+ ALL patients, correspondingly)
achieved BCR-ABL1 mRNA ≤1% as best response. Nine
(27%) patients with CML and 2 (12%) patients with Ph+
ALL did not achieve any response. The median time to best
response was 151 days (range, 26–616) for patients with CML
and 49 days (range, 14–308) for patients with Ph+ ALL.
Among the 20 patients who started ponatinib because of
intolerance to previous TKIs, MMR was achieved as best re-
sponse by 9 (64%) CML and 4 (67%) Ph+ ALL patients and 1
(7%) CML patient achieved BCR-ABL1 mRNA ≤1% (Fig. 4).
The median time to best response in patients who started
ponatinib due to previous TKI intolerance was 159 days (range,
51–431) in patients with CML and 73 days (range, 14–308) in
patients with Ph+ ALL. Among the 30 patients who started
ponatinib for reasons other than intolerance to previous
TKI(s), 10 (53%) patients with CML and 3 (27%) patients with
Ph+ ALL achievedMMR as best response. The median time to
best response in these patients was 140 days (range, 26–616)
and 36 days (range, 19–97), respectively. A sensitivity analysis,
excluding the 3 CML patients in accelerated or blastic phase,
did not show any difference in the percentage of CML patients
who started ponatinib due to intolerance and who achieved
MMR as best response compared to those who did not show
intolerance with MMR as best response.
Estimated OS was 85.3% for CML and 85.6% for Ph+
ALL patients over 3 years of the registry duration. Estimated
Fig. 2 Reasons for starting ponatinib treatment. CML, chronic myeloid
leukemia; Ph+ ALL, Philadelphia chromosome-positive acute lympho-
blastic leukemia; intolerant, those who started ponatinib due to intoler-
ance to previous tyrosine kinase inhibitors (TKIs); non-intolerant, those
who started ponatinib due to reasons other than intolerance to previous
TKIs (progression, T315I mutation, relapse or refractoriness).
Refractoriness to previous TKI in this figure included absence of re-
sponse, primary refractoriness, and hematological or cytogenetic relapse
on previous TKI. Percentages may not add up to 100 due to rounding
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PFS was 81.6% for CML and 48.9% for Ph+ ALL patients
(Fig. 5).
Dose reductions occurred in 20 (61%) CML and 7 (41%)
Ph+ ALL patients, and dose increases occurred in 14 (42%)
and 3 (18%) patients with CML and Ph+ ALL, respectively
(Table 2). Dose reductions or interruptions occurred mostly
due to AEs, but also to prevent future AEs as part of a risk
management strategy in CML and Ph+ALL patients. Reasons
for dose increases in CML patients and Ph+ ALL patients
were absent or poor response and good tolerance to a lower
dose of ponatinib. Treatment interruptions were registered in
11 (33%) CML and 5 (29%) Ph+ ALL patients, with a median
duration of interruption of 24 days (range, 7–126) in CML and
20 days (range, 12–201) in Ph+ ALL patients. In total, 15
CML (45%) and 14 (82%) Ph+ ALL patients terminated the
treatment with ponatinib. Eight CML patients and 3 Ph+ ALL
patients terminated treatment due to an AE.
In general, results in the subgroup of patients who
underwent an allogeneic stem cell transplantation before
starting ponatinib were in line with the overall population.
Of the 8 patients treated in the NPP who were included in this
registry, 6 patients are currently still on treatment and
achieved MMR. These patients have been on ponatinib
treatment from 4 up to 7 years.
Safety
Thirty-four (68%) patients experienced adverse reactions. The
most frequently reported adverse reactions (by ≥10% of
patients) were rash and dry skin (Fig. 6). Other reported adverse
reactions of interest included thrombocytopenia (4), abdominal
pain (4), vascular stenosis (3), arterial hypertension (2), chest
pain (1), palpitations (1), vascular occlusion (1), pancytopenia
(1), increased serum lipase (1), cholecystitis (1), hepatitis (1),
cholestasis (1), pneumonia (1), hyponatremia (1), pancreatitis
(1), and hepatocellular injury (1).
In total, 5 deaths were registered; none of these was
considered by the investigator to be a consequence of the
ponatinib treatment. Three patients suffered from general
physical health deterioration resulting in death and two
patients died from cardiorespiratory arrest induced by euthanasia
(one patient with relapse of Ph+ ALL; one patient with both
metastatic renal cell carcinoma and relapse of Ph+ ALL).
Fig. 3 Swimmer plot displaying treatment duration, treatment
modification, and outcome for each patient. Each bar represents an
individual patient. Patients with CML were in chronic phase, except for
3 indicated patients: orange circle, blastic myeloid phase; purple
circle, accelerated phase; grey circle, blastic lymphoid phase; AE,
adverse event; CCyR, complete cytogenetic response; MMR, major
molecular response; alloSCT, allogeneic stem cell transplantation; TKI,
tyrosine kinase inhibitor
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Discussion
This registry collected data on the use of ponatinib in patients
with CML or Ph+ ALL in routine clinical practice in Belgium.
Data were collected in 20 hospitals that covered most of the
patient population treated with ponatinib in the country. The
results of this registry are in line with those of the PACE
clinical trial [7, 8], although differences in patient population,
size, study design, and follow-up hinder direct comparison.
The median follow-up in this registry was 15 months for patients
with CML and 4.5 months for patients with Ph+ ALL. A longer
follow-up will be possible since this registry will continue for
another 3 years. The number of patients harboring mutations in
this registrywas in linewith PACE [8]. The overall percentage of
patients with CML and Ph+ ALL who achieved MMR as best
response was 58% and 41%, respectively. It should be noted
that information on patients’ responses to any previous TKI
(before starting the registry) was not collected. This limits the
interpretation of the treatment responses as we do not know
whether responses occurred rapidly after starting ponatinib or
whether responses from previous treatment were maintained.
For CP-CML patients, the duration of response in the registry
was in line with the duration seen in the PACE trial. More than
one-third of all patients (42% CML and 35% Ph+ ALL patients)
started ponatinib treatment due to intolerance to previous TKIs.
Cross-intolerance to different TKIs is generally not
considered to be clinically relevant, particularly for non-
hematologic AEs [11]. While 20 patients (14 CML and 6
Ph+ ALL) initially started ponatinib because of intolerance
to previous TKIs, only 1 patient in this registry discontinued
ponatinib treatment due to intolerance. This was a CML pa-
tient who had switched to ponatinib for another reason than
intolerance. From the 20 patients who initially started
ponatinib because of intolerance to previous TKIs, 11
discontinued ponatinib treatment, of which 8 due to an AE
(73%). From the 30 patients who started ponatinib for other
reasons than intolerance, 18 discontinued ponatinib treatment,
of which 3 due to an AE (17%). Patients who discontinued
due either to an AE or to treatment intolerance were consid-
ered to be intolerant in this analysis. It confirms that, even if
some patients are intolerant to multiple TKIs, ponatinib can
still be a valuable option for intolerant patients. While all
patients in PACE initially started ponatinib at a dose of 45
mg/day, dose reductions were recommended subsequently in
CP-CML patients who had achieved MCyR or MMR to
reduce the risk for AOEs [8]. Most of those patients main-
tained their responses despite dose reductions. Based on the
currently approved label, the starting dose of ponatinib is 45
mg/day. However, some patients in this registry received a
lower starting dose. In the few patients who started with
15mg/day, this starting dose did not seem to preclude achieving
MMR. A trend towards reduction of ponatinib starting dose in
CML patients was observed during the course of this registry, as
reflected by the proportion of patients receiving the maximal
starting dose among the first and the last 10 patients enrolled
in the registry. However, these results do not allow us to make
any conclusions in this regard due to the small number of
patients receiving each dose and current study design. While
the recently updated recommendations from the European
LeukemiaNet recommend a lower starting dose for certain
CML patients [5], more data from randomized clinical trials
are needed to further evaluate this. The effect of different starting
doses of ponatinib (15 mg/day, 30 mg/day, and 45 mg/day) on
the occurrence of AEs and on efficacy in CML patients is
currently being evaluated in the prospective dose-ranging trial
OPTIC (Optimizing Ponatinib Treatment in CML, clinicaltrials.
gov identifier: NCT02467270).
Safety outcomeswere similar to those observed in the PACE
trial for the most frequently observed AEs. The incidence
of cardiovascular AEs seemed low in this observational
registry (reported for 8 patients [16%]), even though patient
Fig. 4 Best response to treatment in patients with aCML and b Ph+ ALL
(overall, intolerant and non-intolerant patients). CCyR, complete cytoge-
netic response; CML, chronic myeloid leukemia; MMR, major molecular
response; N, number of patients; Ph+ ALL, Philadelphia chromosome-
positive acute lymphoblastic leukemia. *1 patient had achieved CCyR
before starting treatment with ponatinib. Of note, 2 (6%) patients with
CML and 4 (24%) patients with Ph+ ALL did not have measurable
responses to treatment
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Fig. 5 Kaplan-Meier estimates of overall survival and progression-free
survival in a patients with CML (overall, intolerant and non-intolerant
patients) and b patients with Ph+ ALL (overall, intolerant and non-
intolerant patients). CML, chronic myeloid leukemia; Ph+ ALL,
Philadelphia chromosome-positive acute lymphoblastic leukemia; TKI,
tyrosine kinase inhibitor; OS, overall survival; PFS, progression-free
survival
Table 2 Overview of and reasons
for treatment modifications All patients CML patients Ph+ ALL patients
Treatment modification, n (%) N = 50 N = 33 N = 17
Dose reduction 27 (54) 20 (61) 7 (41)
Dose increase 17 (34) 14 (42) 3 (18)
Treatment interruption 16 (32) 11 (33) 5 (29)
Treatment termination 29 (58) 15 (45) 14 (82)
No change 5 (10) 3 (9) 2 (12)
Reasons for dose reduction/interruption, n’ (%) N’ = 57 N’ = 38 N’ = 19
AE 42 (74) 29 (76) 13 (68)
Prevention 14 (25) 9 (24) 5 (26)
Other 1 (2) - 1 (5)
Reasons for dose increase, n’ (%) N’ = 24 N’ = 19 N’ = 5
No or low response 11 (46) 10 (53) 1 (20)
Good tolerance of treatment 13 (54) 9 (47) 4 (80)
Reasons for treatment termination, n’ (%) N’ = 29 N’ = 15 N’ = 14
AE 11 (38) 8 (53) 3 (21)
Disease progression 4 (14) 1 (7) 3 (21)
Intolerance 1 (3) 1 (7) -
Planned allogeneic stem cell transplantation 6 (21) 1 (7) 5 (36)
Other a 7 (27) 4 (27) 3 (21)
AE adverse event; N total number of patients; N’ total number of treatment modifications (dose increase, dose
decrease/interruption or treatment termination); n (%) number (percentage) of patients in respective category; n’
(%) number (percentage) of treatment modifications in respective category
a This includes the 5 deaths in the registry
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baseline characteristics might indicate certain risk factors for
cardiovascular events. In the PACE trial, 31% of CP-CML
and 25% of Ph+ ALL patients reported treatment-emergent
AOEs of any grade. This difference could be due to the ap-
propriate patient selection andmonitoring, the implementation
of the risk minimization activities, and a possible
underreporting of AEs in a real-life situation as compared to
a clinical trial or shorter follow-up period; this difference was
also observed for the frequency of other AEs. The Common
Terminology Criteria for Adverse Events grading was not
collected for the purpose of this registry, limiting the clinical
interpretation (severity) of the described AEs.
Several retrospective observational studies reporting clinical
use of ponatinib have been published [12–14]. However, to the
best of our knowledge, this Belgian registry is the first to
prospectively evaluate the effectiveness and safety of ponatinib
in routine clinical practice. This nationwide registry collected
quality data from leading hospitals that treat CML and Ph+
ALL patients in Belgium. Although the number of patients
included in the registry was slightly higher compared to
published retrospective studies, the available number of
patients per diagnosis was still too small to allow robust
statistical analysis. Hence, all analyses in this registry were
descriptive.
In conclusion, the results obtained in routine clinical
practice in Belgium are in line with those of the PACE trial,
therefore supporting the use of ponatinib in patients with
CML and Ph+ ALL after failure or intolerance to previous
lines of TKIs or who have the T315I mutation. Major
molecular responses were observed as best response in most
CML patients and a large proportion of Ph+ ALL patients. In
Ph+ ALL patients, deep molecular responses seemed to occur
more frequently in intolerant versus non-intolerant patients.
The registry revealed no new safety signals other than those
previously reported [7, 8]. The collection of registry data is
still ongoing, with the aim of evaluating more patients and
allowing for longer follow-up.
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